Assessment of the FDA Risk Evaluation and Mitigation Strategy (REMS) for Transmucosal Immediate-Release Fentanyl Products
This study uses FDA documents to describe transmucosal immediate-release fentanyl (TIRF) prescribing patterns after the agency’s 2011 REMS intended to reduce the rate of TIRF-related adverse outcomes, misuse, abuse, addiction, and overdose.
